GAITHERSBURG, Md., Jan. 15, 2021 (GLOBE NEWSWIRE)– Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology business developing next-generation vaccines for severe contagious illness, today revealed the visit of Henrietta Ukwu, M.D., FACP, FRAPS, to the position of Senior Vice President, Chief Regulatory and Quality Officer. In this recently produced function, Dr. Ukwu will lead international regulative strategy and execution in addition to the quality assurance function for the business’s development-stage vaccine prospects, including its recombinant protein-based COVID-19 candidate vaccine, NVX-CoV2373

” Dr. Ukwu brings comprehensive regulative affairs and quality expertise and leadership experience at specifically the right time for Novavax, as we advance toward data readouts and regulatory submissions in 2021,” said Stanley C. Erck, President and Ceo, Novavax. “We welcome her medical point of view and intricate knowledge of the regulative process at this remarkable time for the company and the race against the global pandemic.”

Dr. Ukwu most just recently functioned as Chief Regulatory Officer and Global Head of Quality and Regulatory at Otsuka Pharmaceuticals. While there, she globalized and led the regulatory and quality organizations with a concentrate on compliance quality, inspection preparedness, engagement with health authorities and regulatory companies and successful results. Prior to Otsuka, she held senior leadership functions at PPD as Senior Citizen Vice President and Head of Global Regulatory Affairs, where she had responsibilities for regulatory services across all PPD line of work; Wyeth Pharmaceuticals, Inc. (Pfizer), where she was Vice President, Regulatory Affairs, with duty that spanned vaccines, biologics and pharmaceuticals across all areas; and at Merck & Co., Inc., as Head of Vaccine Regulatory Development, Vice President of Global Regulatory Affairs and Global Regulatory Policy. Dr. Ukwu has led approval of lots of products, including for Varivax ®, a chickenpox varicella vaccine, and Crixivan ®, (indinavir), an HIV protease inhibitor that considerably impacted the treatment paradigm of HIV/AIDS.

Dr. Ukwu’s significant contributions to medication, science and the pharmaceutical industry consist of establishing and enhancing the regulative and quality profession, along with functioning as a coach to others who have actually advanced into senior management positions. These contributions have been acknowledged with various prominent awards.

Dr. Ukwu made her medical and surgical degrees from the University of Jos School of Medicine in Nigeria. She finished her residency in internal medication at Baptist Health center, and a fellowship in contagious illness at Vanderbilt University, both in Nashville, Tennessee. She is a Fellow of both the American College of Physicians (FACP) and the Regulatory Affairs Professional Society (FRAPS) and is a pioneer teacher at the Graduate School of Pharmacy at Temple University in Ambler, Pennsylvania.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that promotes enhanced health worldwide through the discovery, advancement and commercialization of innovative vaccines to prevent severe contagious illness. The company’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles created to deal with urgent global health requirements. Novavax is performing late-stage scientific trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the infection that triggers COVID-19 NanoFlu ™, its quadrivalent influenza nanoparticle vaccine, fulfilled all main goals in its pivotal Stage 3 clinical trial in older adults and will be advanced for regulative submission. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M ™ adjuvant to improve the immune reaction and promote high levels of reducing the effects of antibodies.

To learn more, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Novavax Forward Looking Statements
Statements herein connecting to the future of Novavax and the continuous advancement of its vaccine and adjuvant items are forward-looking statements. Novavax warns that these forward-looking statements undergo numerous dangers and uncertainties, which could trigger real outcomes to vary materially from those expressed or suggested by such declarations. These threats and uncertainties consist of those determined under the heading “Danger Elements” in the Novavax Yearly Report on Form 10- K for the year ended December 31, 2019, and Quarterly Report on Form 10- Q for the duration ended September 30, 2020, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place significant reliance on positive statements contained in this press release. You are motivated to read our filings with the SEC, readily available at sec.gov, for a conversation of these and other threats and unpredictabilities. The positive statements in this news release speak only since the date of this file, and we undertake no obligation to update or modify any of the declarations. Our service goes through substantial dangers and unpredictabilities, consisting of those referenced above. Financiers, prospective financiers, and others must think about these threats and unpredictabilities.

 Contacts: Investors Erika Trahan ir@novavax.com 240-268-2022 Media Edna Kaplan media@novavax.com 617-974-8659

Primary Logo

LEAVE A REPLY

Please enter your comment!
Please enter your name here